RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
Zacks Investment Research on MSN
Can Merck's new drugs & pipeline ease Keytruda LOE concerns?
Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results